|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
51,620,000 |
Market
Cap: |
10.32(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.000001 - $0.1993 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Humanigen is a biopharmaceutical company focused on developing its immuno-oncology and immunology portfolio of monoclonal antibodies. Co. is focusing on the development of its key product candidate, lenzilumab, its Humaneered® anti-human GM-CSF immunotherapy, through a clinical research agreement to study the effect of lenzilumab on the safety of Yescarta®, axicabtagene ciloleucel including cytokine release syndrome, and neurotoxicity. Co. is creates combinatory gene-edited CAR-T therapies to improve efficacy. Co. is also developing its own chimeric antigen receptor T-cell programs based on the backbone of ifabotuzumab and HGEN005, in unmet medical need and rare/orphan oncology conditions.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,042,996 |
Total Buy Value |
$0 |
$0 |
$0 |
$2,263,990 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
0 |
0 |
386,350 |
386,350 |
Total Sell Value |
$0 |
$0 |
$4,250 |
$4,250 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shkreli Martin |
10% Owner |
|
2016-08-25 |
4 |
S |
$3.10 |
$5,930,939 |
D/D |
(1,913,206) |
309,723 |
|
- |
|
Nomis Bay Ltd. |
10% Owner |
|
2016-06-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,719,006 |
|
- |
|
Black Horse Capital Master Fund Ltd. |
10% Owner |
|
2016-06-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,948,758 |
|
- |
|
Barliant Ronald |
Director |
|
2016-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
93,786 |
93,786 |
|
- |
|
Durrant Cameron |
Chairman and CEO |
|
2016-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
135,583 |
135,583 |
|
- |
|
Moradi David |
Director |
|
2015-12-16 |
4/A |
B |
$29.32 |
$99,981 |
I/I |
3,410 |
178,210 |
2.25 |
- |
|
Moradi David |
Director |
|
2015-12-16 |
4/A |
B |
$29.32 |
$99,981 |
D/D |
3,410 |
178,210 |
3.92 |
- |
|
Harrison Michael Wayne |
Director |
|
2015-12-16 |
4 |
B |
$29.32 |
$49,991 |
D/D |
1,705 |
1,705 |
2.39 |
- |
|
Biestek Marek |
See Remarks |
|
2015-12-16 |
4 |
B |
$29.32 |
$293,200 |
D/D |
10,000 |
250,000 |
2.39 |
- |
|
Fernandez Thomas Edward |
Director |
|
2015-12-16 |
4 |
B |
$29.32 |
$199,992 |
D/D |
6,821 |
6,821 |
2.39 |
- |
|
Moradi David |
Director |
|
2015-12-16 |
4 |
B |
$29.32 |
$99,981 |
I/I |
3,410 |
378,210 |
2.25 |
- |
|
Moradi David |
Director |
|
2015-12-16 |
4 |
B |
$29.32 |
$99,981 |
D/D |
3,410 |
378,210 |
3.92 |
- |
|
Shkreli Martin |
Chief Executive Officer |
|
2015-11-24 |
4 |
B |
$38.15 |
$190,750 |
D/D |
5,000 |
2,075,200 |
3.23 |
- |
|
Shkreli Martin |
Chief Executive Officer |
|
2015-11-20 |
4 |
B |
$18.88 |
$94,400 |
D/D |
5,000 |
2,070,200 |
3.23 |
- |
|
Moradi David |
10% Owner |
|
2015-11-18 |
4 |
B |
$2.13 |
$319,500 |
I/I |
150,000 |
574,800 |
1.5 |
- |
|
Moradi David |
10% Owner |
|
2015-11-18 |
4 |
B |
$2.13 |
$319,500 |
D/D |
150,000 |
574,800 |
2.45 |
- |
|
Biestek Marek |
See Remarks |
|
2015-11-18 |
4 |
B |
$2.04 |
$81,600 |
D/D |
40,000 |
240,000 |
2.44 |
- |
|
Shkreli Martin |
10% Owner |
|
2015-11-18 |
4 |
B |
$2.02 |
$888,800 |
D/D |
440,000 |
2,065,200 |
2.45 |
- |
|
Biestek Marek |
See Remarks |
|
2015-11-17 |
4 |
B |
$1.83 |
$247,050 |
D/D |
135,000 |
200,000 |
2.44 |
- |
|
Moradi David |
Managing Member |
|
2015-11-17 |
4/A |
B |
$1.69 |
$192,322 |
I/I |
113,800 |
424,800 |
0.01 |
- |
|
Moradi David |
Managing Member |
|
2015-11-17 |
4/A |
B |
$1.69 |
$192,322 |
D/D |
113,800 |
424,800 |
2.44 |
- |
|
Anthion Partners Ii Llc |
10% Owner |
|
2015-11-17 |
4 |
B |
$1.69 |
$192,322 |
I/I |
113,800 |
424,800 |
1.5 |
- |
|
Anthion Partners Ii Llc |
10% Owner |
|
2015-11-17 |
4 |
B |
$1.69 |
$192,322 |
D/D |
113,800 |
424,800 |
2.45 |
- |
|
Shkreli Martin |
10% Owner |
|
2015-11-17 |
4 |
B |
$1.93 |
$1,187,897 |
D/D |
613,677 |
1,625,200 |
2.45 |
- |
|
Biestek Marek |
See Remarks |
|
2015-11-16 |
4 |
B |
$1.36 |
$88,400 |
D/D |
65,000 |
65,000 |
2.44 |
- |
|
160 Records found
|
|
Page 6 of 7 |
|
|